OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
9
Results
Show all
Save search
Copy query
Show results for
Unknown
(9)
Publication Date
Release Date
2022
(3)
2024
(2)
2023
(2)
2021
(1)
2010
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
A Truncated Isoform of Cyclin T1 Could Contribute to the Non-Permissive HIV-1 Phenotype of U937 Promonocytic Cells.
Not available
S-EPMC11359826
|
biostudies-literature
Cite
Protective anti-tumor vaccination against glioblastoma expressing the MHC class II transactivator CIITA.
Not available
S-EPMC10040613
|
biostudies-literature
Cite
A Panel of Eight miRNAs Is Deregulated in HTLV-2 Infected PBMCs and BJABGu Cell Line.
Not available
S-EPMC9320395
|
biostudies-literature
Cite
Mucosal immune response after the booster dose of the BNT162b2 COVID-19 vaccine.
Not available
S-EPMC9828819
|
biostudies-literature
Cite
The endogenous HBZ interactome in ATL leukemic cells reveals an unprecedented complexity of host interacting partners involved in RNA splicing.
Not available
S-EPMC9376625
|
biostudies-literature
Cite
CIITA-Transduced Glioblastoma Cells Uncover a Rich Repertoire of Clinically Relevant Tumor-Associated HLA-II Antigens.
Not available
S-EPMC8724627
|
biostudies-literature
Cite
T Cell Responses to BA.2.86 and JN.1 SARS-CoV-2 Variants in Elderly Subjects.
Not available
S-EPMC11680353
|
biostudies-literature
Cite
Mucosal immune response in BNT162b2 COVID-19 vaccine recipients.
Not available
S-EPMC8718969
|
biostudies-literature
Cite
Efficacy of n-3 polyunsaturated fatty acids and feasibility of optimizing preventive strategies in patients at high cardiovascular risk: rationale, design and baseline characteristics of the Rischio and Prevenzione study, a large randomised trial in general practice.
Not available
S-EPMC2909229
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets